U.K. specialist health care group BTG PLC has transformed its business and set an ambitious goal for long-term growth: annualized sales of $1 billion by the end of fiscal 2021, up from sales of $150 million for the fiscal year 2014 (ended March 31). Through acquisitions and strategic planning, BTG has morphed from a development-stage life sciences company with a broad portfolio to a niche specialist health care business with an emphasis on interventional medicines.
The company’s long-term financial target is based on organic growth, which the company expects will be driven by growth in drug/device oncology offerings, its EKOS ultrasound-poweredblood clot-removal franchise, and by building the